Donepezil for dementia due to Alzheimer's disease (Q24244938)

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

Severe impairment battery. A neuropsychological test for severely demented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Donepezil therapy in clinical practice: a randomized crossover study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Use of donepezil for the treatment of mild-moderate Alzheimer's disease: an audit of the assessment and treatment of patients in routine clinical practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

1 reference

7 January 2021

A new rating scale for dementia syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

AD2000: donepezil in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Donepezil for nursing home patients with dementia: a reinterpretation of the evidence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Bias in treatment assignment in controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Vitamin E and donepezil for the treatment of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Another advertisement for donepezil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Donepezil delay to nursing home placement study is flawed

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Delay in nursing home placement with donepezil

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Quantitative EEG changes in Alzheimer patients during long-term donepezil therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001190.PUB2

7 January 2021

10.1002/14651858.CD001190.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1367670

1367670

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference